SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:c7e785a3-5210-4762-a876-a638d3004bfe"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:c7e785a3-5210-4762-a876-a638d3004bfe" > Population-based ra...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004903naa a2200529 4500
001oai:lup.lub.lu.se:c7e785a3-5210-4762-a876-a638d3004bfe
003SwePub
008220307s2022 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/c7e785a3-5210-4762-a876-a638d3004bfe2 URI
0247 a https://doi.org/10.1111/bju.156832 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Rannikko, Anttiu Helsinki University Central Hospital,University of Helsinki4 aut
2451 0a Population-based randomized trial of screening for clinically significant prostate cancer ProScreen : a pilot study
264 c 2022-01-08
264 1b Wiley,c 2022
520 a Objectives: To evaluate the feasibility of a population-based screening trial using prostate-specific antigen (PSA), a kallikrein panel and multiparametric magnetic resonance imaging (MRI) aimed at minimizing overdiagnosis, while retaining mortality benefit. Patients and Methods: Feasibility of the screening algorithm was evaluated in terms of participation, screening test results and cancer detection. A random sample of 400 men aged 65 years was identified from the population registry and invited for screening with three stepwise tests (PSA, kallikrein panel and MRI). Men with PSA levels ≥3 ng/mL were further tested with the kallikrein panel, and those with positive findings (risk >7.5%) were referred for prostate MRI. Men with positive MRI (Prostate Imaging Reporting and Data System [PI-RADS] score 3–5) had targeted biopsies only. Men with negative MRI, but PSA density ≥0.15 underwent systematic biopsies. Results: Of the 399 men invited, 158 (40%) participated and 27 had PSA levels ≥3 ng/mL (7% of the invited and 17% of the participants). Of these, 22 had a positive kallikrein panel (6% of the invited and 81% of the PSA-positive men). Finally, 10 men (3% of the invited and 45% of 4Kscore [kallikrein panel]-positive) had a suspicious MRI finding (PI-RADS score ≥3) and five were diagnosed with a clinically significant prostate cancer (Gleason Grade Group [GG] ≥2) at fusion biopsy (3% of the participants), with two GG 1 cases (1%). Additional testing (kallikrein panel and MRI) after PSA reduced biopsies by 56%. Conclusion: The findings constitute proof of principle for our screening protocol, as we achieved a substantial detection rate for clinically significant cancer with few clinically insignificant cases. Participation, however, was suboptimal.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Leht, Mareu University of Tampere,Hyvinkää Hospital4 aut
7001 a Mirtti, Tuomasu University of Helsinki4 aut
7001 a Kenttämies, Anu4 aut
7001 a Tolonen, Teemu4 aut
7001 a Rinta-Kiikka, Irinau Tampere University Hospital4 aut
7001 a Kilpeläinen, Tuomas P.u Helsinki University Central Hospital,University of Helsinki4 aut
7001 a Natunen, Kariu University of Tampere4 aut
7001 a Lilja, Hansu Lund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Clinical Chemistry, Malmö,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Memorial Sloan-Kettering Cancer Center4 aut0 (Swepub:lu)klke-hli
7001 a Lehtimäki, Terho4 aut
7001 a Raitanen, Janiu University of Tampere,UKK Institute for Health Promotion Research4 aut
7001 a Kujala, Paula4 aut
7001 a Ronkainen, Johannau Tampere University Hospital4 aut
7001 a Matikainen, Mikau Helsinki University Central Hospital4 aut
7001 a Petas, Anssiu Helsinki University Central Hospital4 aut
7001 a Taari, Kimmou Helsinki University Central Hospital4 aut
7001 a Tammela, Teuvou Tampere University Hospital,University of Tampere4 aut
7001 a Auvinen, Anssiu University of Tampere4 aut
7102 a Helsinki University Central Hospitalb University of Helsinki4 org
7730 t BJU Internationald : Wileyg 130:2, s. 193-199q 130:2<193-199x 1464-4096x 1464-410X
8564 u http://dx.doi.org/10.1111/bju.15683x freey FULLTEXT
8564 u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bju.15683
8564 8u https://lup.lub.lu.se/record/c7e785a3-5210-4762-a876-a638d3004bfe
8564 8u https://doi.org/10.1111/bju.15683

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy